| 前收盘价格 | 118.70 |
| 收盘价格 | 122.10 |
| 成交量 | 980,125 |
| 平均成交量 (3个月) | 994,837 |
| 市值 | 7,118,461,952 |
| 预期市盈率 (P/E Forward) | 2.50 |
| 价格/销量 (P/S) | 13.57 |
| 股市价格/股市净资产 (P/B) | 10.66 |
| 52周波幅 | |
| 利润日期 | 17 Feb 2026 |
| 营业毛利率 | -30.57% |
| 营业利益率 (TTM) | -19.39% |
| 稀释每股收益 (EPS TTM) | -2.27 |
| 季度收入增长率 (YOY) | 24.60% |
| 总债务/股东权益 (D/E MRQ) | 14.09% |
| 流动比率 (MRQ) | 6.49 |
| 营业现金流 (OCF TTM) | -45.97 M |
| 杠杆自由现金流 (LFCF TTM) | -17.66 M |
| 资产报酬率 (ROA TTM) | -6.68% |
| 股东权益报酬率 (ROE TTM) | -20.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | Glaukos Corporation | 看涨 | 看跌 |
AIStockmoo 评分
-0.4
| 分析师共识 | 4.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.40 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.33% |
| 机构持股比例 | 101.71% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Brown Capital Management Llc | 30 Sep 2025 | 762,760 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 160.00 (Stifel, 29.10%) | 购买 |
| 中 | 140.00 (12.96%) | |
| 低 | 125.00 (Citigroup, 0.86%) | 购买 |
| 平均值 | 139.13 (12.26%) | |
| 总计 | 8 购买 | |
| 平均价格@调整类型 | 117.28 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 18 Feb 2026 | 131.00 (5.70%) | 购买 | 121.00 |
| 28 Jan 2026 | 131.00 (5.70%) | 购买 | 123.94 | |
| Needham | 18 Feb 2026 | 127.00 (2.47%) | 购买 | 121.00 |
| 14 Jan 2026 | 125.00 (0.86%) | 购买 | 104.43 | |
| Wells Fargo | 18 Feb 2026 | 135.00 (8.92%) | 购买 | 121.00 |
| Stifel | 22 Jan 2026 | 160.00 (29.09%) | 购买 | 125.90 |
| Stephens & Co. | 02 Jan 2026 | 145.00 (16.99%) | 购买 | 110.72 |
| UBS | 23 Dec 2025 | 145.00 (16.99%) | 购买 | 116.18 |
| Truist Securities | 18 Dec 2025 | 145.00 (16.99%) | 购买 | 113.21 |
| Citigroup | 11 Dec 2025 | 125.00 (0.86%) | 购买 | 109.23 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | - | 119.17 | -4,059 | -483,711 |
| GILLIAM JOSEPH E | - | 119.17 | -1,057 | -125,963 |
| NAVRATIL TOMAS | - | 119.17 | -396 | -47,191 |
| 累积净数量 | -5,512 | |||
| 累积净值 ($) | -656,865 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 119.17 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| GILLIAM JOSEPH E | 职员 | 24 Feb 2026 | 处理 (-) | 1,057 | 119.17 | 125,963 |
| NAVRATIL TOMAS | 职员 | 24 Feb 2026 | 处理 (-) | 396 | 119.17 | 47,191 |
| BURNS THOMAS WILLIAM | 职员 | 24 Feb 2026 | 处理 (-) | 4,059 | 119.17 | 483,711 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合